How TIPS may improve muscle loss in cirrhosis and the role of FGF21
Official title: Mechanism of Transjugular Intrahepatic Portosystemic Shunt to Improve Sarcopenia by Down-regulation of FGF21
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06794853 · Data updated 2026-11-12
This project tests whether TIPS helps people with cirrhosis regain muscle and whether blood FGF21 levels explain that improvement.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | December 1, 2027 |
| Study ends | December 2027 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT06794853 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with diagnosed liver cirrhosis who are scheduled for TIPS and can give informed consent are ideal candidates.
✕Probably not a fit
Patients with active malignancy, recent major surgery or trauma, serious cardiovascular/cerebrovascular disease, cognitive impairment, or on certain immune‑suppressing treatments are excluded and may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with cirrhosis undergoing TIPS will be followed and divided into groups based on whether their sarcopenia improves after the procedure. Blood samples will be collected over time to measure serum FGF21 while imaging and functional tests will track muscle mass, strength, and performance. The study will compare changes in FGF21 and clinical muscle measures between patients who improve and those who do not. The combined value of FGF21 and muscle function indicators will be analyzed for predicting outcomes after TIPS.
Why it matters
Potential benefit: If successful, the study could identify a blood marker and mechanism linking TIPS to muscle recovery, helping clinicians predict who will benefit and tailor post‑TIPS care.
How similar studies have gone: Previous clinical reports have shown TIPS can improve muscle mass and function in some cirrhotic patients, but the mechanism and the role of biomarkers like FGF21 remain largely unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosed with liver cirrhosis and needing TIPS surgical treatment; 2. Aged between 18-80 years old; 3. Able to understand and sign the informed consent form and willing to cooperate in completing the examinations and follow-up visits. Exclusion Criteria: 1. Combination of serious cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, severe heart failure, etc.); 2. Suffering from malignant tumors and in the active stage; 3. Recent (within 3 months) history of major surgeries or traumas; 4. The presence of mental illness or cognitive disorders, which are unable to cooperate with the study; 5. Undergoing other special treatments that may affect the results of the study (such as certain specific immune-suppressing agents, hormones, etc.)
Where it's running
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Taiwan Recruiting
Study contacts
- Study coordinator: Jiacheng Liu Dr.
- Email: 1946046224@qq.com
- Phone: 18627162379
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TIPS procedure with or without oral branched-chain amino acids (BCAA)
This test will try giving oral BCAA supplements for three months after TIPS in adults with cirrhosis and sarcopenia to see if it improves muscle and clinical outcomes.
-
Prehab and Creatine/Whey Supplements in Cirrhosis-Related Frailty
This study tests whether a digital prehabilitation app plus creatine and whey protein can help maintain muscle health in people with cirrhosis and frailty.
-
Assessing muscle mass and strength in patients with cirrhosis
This study is testing how muscle mass and strength change in people with cirrhosis to see how it affects their daily lives and health.
-
Exploring muscle composition's impact on liver transplant outcomes
This study is testing how muscle health affects the success of liver transplants in patients with severe liver disease.
-
Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis
This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.